Human DNA topoisomerase II: Biochemistry and role in chemotherapy resistance (Review)

Anticancer Research

Volumn 16, Issue 4 A, 1996, Pages 1867-1880

  Withoff, S ^a   De Jong, S ^a   De Vries, E G E ^a   Mulder, N H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

DNA topoisomerase II ; Drug resistance; Human DNA topoisomerase II

Indexed keywords

ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); ENZYME INHIBITOR; TRANSCRIPTION FACTOR;

ARTICLE; CANCER CELL; CATALYSIS; DRUG RESISTANCE; ENZYME ACTIVITY; ENZYME MODIFICATION; HUMAN; PRIORITY JOURNAL; TRANSCRIPTION REGULATION; TUMOR CELL LINE; TUMOR RESISTANCE;

ANIMALS; ANTINEOPLASTIC AGENTS; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; NEOPLASMS; POINT MUTATION; PROMOTER REGIONS (GENETICS); PROTEIN FOLDING; SEQUENCE DELETION; TRANSCRIPTION, GENETIC;

EID: 0029738912     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (184)

1. Drolet M, Wu HY and Liu LF: Roles of DNA topoisomerases in transcription. Adv Pharmacol 29A: 135-146, 1994.
2. Osheroff N, Zechiedrich EL and Gale KC: Catalytic function of DNA topoisomerase II. BioEssays 13: 269-275, 1991.
3. Roca J and Wang JC: DNA transport by a type II DNA topoisomerase: Evidence in favor of a two gate mechanism. Cell 77: 609-616, 1994.
4. Juan CC, Hwang J, Liu AA, Whang-Peng J, Knutsen T, Huebner K, Croce CM, Zhang H, Wang JC and Liu LF: Human DNA topoisomerase I is encoded by a single-copy gene that maps to chromosome region 20q12-13.2. Proc Natl Acad Sci USA 85: 8910-8913, 1988.
5. Tan KB, Dorman TE, Falls KM, Chung TDY, Mirabelli CK, Crooke ST and Mao JI: Topoisomerase-IIα and Topoisomerase-IIß Genes - Characterization and mapping to human chromosome-17 and chromosome-3, respectively. Cancer Res 52: 231-234, 1992.
6. Huang WM: Type II DNA topoisomerase genes. Adv Pharmacol 29A: 210-225, 1994.
7. D'Arpa P and Liu LF: Topoisomerase-targeting antitumor drugs. Biochim Biophy Acta 989: 163-177,1989.
8. Aisner J, Doyle A and Egorin MJ, Chairmen: Topoisomerase inhibitors conference, University of Maryland Cancer Center, Monterey, California, USA. Cancer Chemother Pharmacol 34 (Suppl): 1-134, 1994.
9. Pommier Y, Leteurtre F, Fesen MR, Fujimori A, Bertrand R, Solary E, Kohlhagen G and Kohn K: Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest 12: 530-542, 1994.
10. Osheroff N, Corbett AH and Robinson MJ: Mechanism of action of topoisomerase II-targeted antineoplastic drugs . Adv Pharmacol 29B: 105- 126, 1994.
11. Andersen AH, Svejstrup JO and Westergaard O: The DNA binding, cleavage, and religation reactions of eukaryotic topoisomerases I and II. Adv Pharmacol 29A: 83-101, 1994.
12. Pienta KJ, Partin AW, Coffey DS: Cancer as a disease of DNA organization and dynamic cell structure. Cancer Res 49: 2525-2532, 1989.
13. Hirose S and Suzuki Y: In vitro transcription of eukaryotic genes is affected differently by the degree of DNA supercoiling. Proc Natl Acad Sci USA 85: 718-722, 1988.
14. Liu LF and Wang JC: Supercoiling of the DNA template during transcription. Proc Natl Acad Sci USA 84: 7024-7027, 1987.
15. Adachi Y, Kas E and Laemmli UK: Preferential, cooperative binding of DNA topoisomerase II to scaffold-associated regions. EMBO J 8: 3997-4006, 1989.
16. Kas E and Laemmli U: In vivo topoisomerase II cleavage of the Drosophila histone and satellite III repeats. DNA sequence and structural characteristics. EMBO J 11: 705-716, 1992.
17. Berrios M, Osheroff N and Fisher PA: In situ localization of DNA topoisomerase II, a major polypeptide component of the Drosophila nuclear matrix fraction. Proc Natl Acad Sci USA 82: 4142-4146, 1985.
18. Nitiss JL: Roles of DNA topoisomerases in chromosomal replication and segregation. Adv Pharmacol 29A: 103-134, 1994.
19. Sikorav JL and Jannink G: Kinetics of chromosome condensation in the presence of topoisomerases: a phantom chain model. Biophys J 66: 827-837, 1994.
20. Webb CF, Eneff KL and Drake FH: A topoisomerase II-like protein is part of an inducible DNA binding protein complex that binds 5' of an immunoglobin promoter. Nucleic Acids Res 21: 4363 4368, 1993.
21. Brou C, Kuhn A, staub A, Chaudhary S, Grumm I, Davidson I and Tora L: Sequence-specific transactivators counteract topoisomerase II-mediated inhibition of in vitro transcription by RNA polymerases I and II. Nucleic Acid Res 21: 4011-4018, 1993.
22. Downes CS and Johnson RT: DNA topoisomerases and DNA repair. BioEssays 8: 179-184, 1988.
23. Stevnsner T and Bohr VA: Studies on the role of topoisomerases in general, gene- and strand specific DNA repair. Carcinogenesis 14: 1841-1850, 1993.
24. Scheer U and Benavente R: Functional and dynamic aspects of the mammalian nucleolus. BioEssays 12: 14-21, 1990.
25. Zini N, Santi S, Ognibene A, Bavelloni A, Neri LM, Valmori A, Mariant E, Negri C, Astaldi Ricotti GCB and Maraldi NM. Discrete localization of different DNA topoisomerases in HeLa and K562 cell nuclei and subnuclear fractions. Exp Cell Res 210: 335-348, 1994.
26. DiNardo S, Voelkel K and Sternglanz R: DNA topoisomerase II mutant of Saccharomyces cerevisiae: topoisomerase II is required for segregation of daughter molecules at the termination of DNA replication. Proc Natl Acad Sci USA 81: 2616-2620, 1984.
27. Holm C, Goto T, Wang JC and Botstein D: DNA topoisomerase II is required at the time of mitosis in yeast. Cell 41: 553-563, 1985.
28. Uemura T and Yanagida M: Mitotic spindle pulls hut tails to separate chromosomes in type II DNA topoisomerase mutants: uncoordinated mitosis. EMBO J 5: 1003-1010, 1986.
29. Harker WG, Slade DL, Parr RL, Feldhotf PW, Sullivan DM and Holguin MH: Alterations in the topoisomerase lia gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase IIß enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line. Cancer Res 55: 1707-1716, 1995.
30. Van der Zee AGJ, Hollema H, De Jong S, Boonstra H, Gouw A. Willemse PHB, Zijlstra JG and De Vries EGE: P-Glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of ovary, before and after platinum/ cyclophosphamide chemotherapy. Cancer Res 51: 5915-5920, 1991.
31. Van der Zee AGE. De Jong S, Keith WN, Hollema H, Boonstra H and De Vries EGE: Quantitative and qualitative aspects of topoisomerase I and IIα and ß in untreated and platinum/cyclophosphamide treated malignant ovarian tumors. Cancer Res 54: 749-755, 1994.
32. Withoff S, Keith WN, Coutts J, Nienhuis EF, Hoare S, Mulder NH and De Vries EGE: Decreased TopoIIα gene copy number explains decreased Topolla mRNA and protein levels and decreased TopoII activity in TopoII-drug resistant SCLC cell lines. Proc Am Assoc Cancer Res 36: #2671, 1995.
33. Murphy DS, McHardy P, Coutts J, Mallon EA, George WD, Kayc SB, Brown R and Keith WN: Interphase cytogenetic analysis of erbB2 and topollα co-amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ, Int J Cancer 64: 18-26, 1995.
34. Coutts J, Plumb JA, Brown R and Keith WN: Expression of topoisomerase II alpha and beta in an adenocarcinoma cell line carrying amplified topoisomerase II alpha and retinoic acid receptor alpha genes. Br J Cancer 68: 793-800, 1993.
35. Smith K, Houlbrook S, Greenall M, Carmichael J and Harris AL: Topoisomerase II alpha coamplification with erbB2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity. Oncogene 8: 933-938, 1993.
36. Beck WT, Danks MK, Wolverton JS, Chen M, Granzen B, Kim R and Suttle DP: Resistance of mammalian tumor cells to inhibitors of DNA topoisomerase II. Adv Pharmacol 29b: 145-169, 1994.
37. Mirski SEL and Cole SPC: Cytoplasmic localization of a mutant Mr 160,000 topoisomerase IIα is associated with the loss of putative bipartite nuclear localization signals in a drug-resistant human lung cancer cell line. Cancer Res 55: 2129-2134, 1995.
38. Kemp BE and Pearson RB: Trends in Biochem Sciences 15: 342-346, 1990.
39. Austin CA, Sng JH, Patel S and Fisher LM: Novel HeLa topoisomerase II is the IIß isoform: complete coding sequence and homology with other type II topoisomerases. Biochim Biophys Acta 1172: 283-291, 1993.
40. Davies SL, Jenkins JR and Hickson ID: Human cells express two differentially spliced forms of topoisomerase IIa mRNA. Nucl Acids Res 21: 3719-3723, 1993.
41. Drake FH, Hofmann GA, Bartus HF, Mattern MR, Crooke ST and Mirabelli CK: Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry 28: 8154-8160, 1989.
42. Tsai-Pflugfelder M, Liu LF, Liu AA, Tewey KM, Whang-Peng J, Knutsen T, Huebner K, Croce CM and Wang JC: Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22. Proc Natl Acad Sci USA 85: 7177-7181, 1988.
43. Jenkins JR, Ayton P, Jones T, Davies SL, Simmons DL, Harris AL, Sheer D and Hickson ID: Isolation of cDNA clones encoding the beta-isozyme of human DNA topoisomerase-II and localization of the gene to chromosome 3p24. Nucl Acids Res 20: 5587-5592, 1992.
44. Danks MK, Qiu J, Catapano CV, Schmidt CA, Beck WT and Fernandes DJ: Suhcellular distribution of the α and ß topoisomerase II-DNA complexes stabilized by VM26. Biochem Pharmacol 48: 1785-1795, 1994.
45. Woessner, RD, Mattern MR, Mirabelli CK, Johnson RK and Drake FH: Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomeraseII in NIH-3T3 cells. Cell Growth Differ 2: 209-214, 1991.
46. Kroll DJ and Rowe TC: Phosphorylation of DNA topoisomerase II in a human tumor cell line. J Biol Chem 266: 7957-7961, 1991.
47. Heck MMS, Hittelman WN and Earnshaw WC: Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle. Proc Natl Acad Sci USA 85: 1086-1090, 1988.
48. Kimura K, Saijo M, Ui M and Enomoto T: Growth state- and cell cycledependent fluctuation in the expression of two forms of DNA topoisomerase II and possible specific modification of the higher molecular weight form in the M phase. J Biol Chem 269: 1173-1176, 1994.
49. Kimura K, Nozaki N, Saijo M, Kikuchi A, Ui M and Enomoto T: Identification of the nature of modification that causes the shift of DNA topoisomerase IIß to apparent higher molecular weight forms in the M phase. J Biol Chem 269: 24523-24526, 1994.
50. Woessner RD, Chung TDY, Hofmann GA, Mattern MR, Mirabelli CK, Drake FH and Johnson RK: Differences between normal and ras-transformed NIH-3T3 cells in expression of the 170 kD and 180 kD forms of topoisomerase II. Cancer Res 50: 2901-2908, 1990.
51. Prosperi E, Sala E, Negri C, Oliani C, Supino R, Astraldi Ricotti GBC, Bottiroli G: Topoisomerase IIα and ß in human tumor cells grown in vitro and in vivo. Anticancer Res 12: 2093-2100, 1992.
52. Hochhauser D, Stanway CA, Harris AL and Hickson ID: Cloning and characterization of the 5′-flaning region of the human topoisomerase IIα gene. J Biol Chem 267: 18961-18965, 1993.
53. Loflin PT, Hochhauser D, Hickson ID, Morales F and Zwelling LA: Molecular analysis of a potentially phorbol-regulatable region of the human topoisomerase IIα gene promotor. Biochem Biophys Res Commun 200: 489-496, 1994.
54. Loflin PT, Hochhauser D, Hickson ID, Morales F and Zwelling L: Molecular analysis of a potentially phorbol-regulatable region of the human topoisomerase II alpha gene promoter. Biochem Biophys Res Commun 200: 489-496, 1994.
55. Brandt TL, Fraser DJ, Leal S and Kroll DJ: c-Myb transactivates the human topoisomerase IIα gene promoter in HL-60 cells. Proc Am Assoc Cancer Res 36: #2691, 1995.
56. Fraser DJ, Brandt TL and Kroll DJ: Topoisomerase IIα promoter trans-activation early in monocytic differentiation of HL-60 human leukemia cells. Mol Pharmacol 47: 696-706, 1995.
57. Tsao YP, Tsao LT, Hsu SL and Chen SL: Retinoic acid represses the gene expression of topoisomerase II in HEP3B cells. Cancer Lett, 87: 73-77, 1994.
58. Pommier Y, Orr A, Kohn KW and Riou J-F: Differential effects of amsacrine and epipodophyllotoxins on topoisomerase II cleavage in the human c-myc protooncogene. Cancer Res 52: 3125-3130, 1992.
59. Bunch RT, Povirk LF, Orr MS, Randolph JK, Fornari FA and Gewirtz DA: Influence of amsacrine (mAMSA) on bulk and genespecific DNA damage and c-myc expression in MCF-7 breast tumor cells. Biochem Pharmacol 47: 317-329, 1994.
60. Kroll DJ, Sullivan DM, Gutierrez-Hartman A and HoeMer JP: Modification of DNA topoisomerase II activity via direct interaction with the cyclic adenosine-3′,5′-monophosphate response element binding protein and related transcription factors. Mol Endocrinol 7: 305-318, 1993.
61. DeVore RF, Corbett AH and Osheroff N: Phosphorylation of topoisomerase II by casein kinase II and protein kinase C: Effects of enzyme-mediated DNA cleavage/religation and sensitivity to the antineoplastic drugs etoposide and 4′-(9-acridinylamino)methanesulfon-m-anisidide. Cancer Res 52: 2156-2161, 1992.
62. Sahyoun N, Wolf M, Besterman J, Hsieh T-S, Sander M, LeVine III H, Chang K-J and Cuatrecasas P: Protein kinase C phosphorylates topoisomerase II: topoisomerase activation and its possible role in phorbol ester-induced differentiation of HL-60 cells. Proc Natl Acad Sci USA 83: 1603-1607, 1986.
63. Cardenas ME, Dang O, Glover CVC and Gasser SM: Casein kinase-II phosphorylates the eukaryote specific C-terminal domain of topoisomerase-II in vivo. EMBO J 11: 1785-1796, 1992.
64. Wells NJ, Addison CM, Fry AM, Ganapathi R and Hickson ID: Serine 1524 is a major site of phosphorylation on human topoisomerase II alpha protein in vivo and is a substrate for casein kinase in vitro. J Biol Chem 269: 29746-29751, 1994.
65. Bojanowski K, Filhol O, Cochet C, Chambaz EM and Larsen AK: DNA topoisomerase II and casein kinase II associate in a molecular complex that is catalytically active. J Biol Chem 268: 22920-22926, 1993.
66. Fry AM and Hickson ID: Phosphorylation modulates the enzymatic activity of human topoisomerase IIα protein. Proc Am Assoc Cancer Res. 34: #2511, 1993.
67. Darby MK, Smitt B, Jongstra-Bilen J and Vosberg HP: Inhibition of calf thymus type II DNA topoisomerase by poly (ADP-ribosylation). EMBO J 4: 2129-2134, 1985.
68. Liu LF: DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58: 351-375, 1989.
69. Froelich-Ammon SJ, Gale KC and Osheroff N: Site-specific cleavage of a DNA hairpin by topoisomerase II. DNA secondary structure as a determinant of enzyme recognition/cleavage. J Biol Chem 269: 7719-7725, 1994.
70. Capranico G, Palumbo M, Tinelli S, Mabilia M, Pozzan A and Zunino F: Conformational drug determinants of the sequence specificity of drug-stimulated topoisomerase II DNA cleavage. J Mol Biol 235: 1218-1230, 1994.
71. Pommier Y, Capranico G, Orr A and Kohn KW: Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amsacrine or teniposide. Nucl Acids Res 19: 5973-5980, 1991.
72. Ross W, Rowe T, Glisson B, Yalowich J and Liu L: Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage. Cancer Res 44: 5857-5860, 1984.
73. Epstein RJ and Smith PJ: Estrogen-induced potentiation of DNA damage and cytotoxicity in human breast cancer cells treated with topoisomerase II-interactive antitumor drugs. Cancer Res 48: 297-303, 1988.
74. Covey JM, Kohn KW, Kerrigan D, Tilchen EJ and Pommier Y: Topoisomerase II-mediated DNA damage produced by 4′-(9-acridinylamino)-methanesulfon-m-aniside and related acridities in L1210 cells and isolated nuclei: relation to cytotoxicity. Cancer Res 48: 860-865, 1988.
75. Long BH, Musial ST and Brattain MG. DNA breakage in human lung carcinoma cells and nuclei that are naturally sensitive or resistant to etoposide and teniposide. Cancer Res 46: 3809-3816, 1986.
76. Estey EH, Silberman L, Beran M, Andersson BS and Zwelling LA: The interaction between nuclear topoisomerase II activity from human leukemia cells, exogenous DNA, and 4′-(9acridinylamino)methanesulfon-m-aniside (m-AMSA) or 4′-(4,6-O-ethylidene-ß-D-glucopyranoside) (VP-16) indicates the sensitivity of the cells to the drugs. Biochem Biophys Res Comm 47: 787-793, 1987.
77. Covey JM, Kohn KW, Kerrigan D, Tilchen EJ and Pommier Y: Topoisomerase II-mediated DNA damageproducedby 4′-(9-acridinylamino)-methanesulfon-m-anisidide and related acridines in L1210 cells and isolated nuclei: Relation to cytotoxicity. Cancer Res 48: 860-865, 1988.
78. Fox ME and Smith PJ: Long-term inhibition of DNA synthesis and the persistence of trapped topoisomerase II complexes in determining the toxicity of the antitumor DNA intercalators mAMSA and mitoxantrone. Cancer Res 50: 5813-5818, 1990.
79. Fry AM, Chresta CM, Davies SM, Walker MC, Harris AL, Hartley JA, Masters JRW and Hickson ID: Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines. Cancer Res 51: 6592-6595, 1991.
80. Sullivan DM, Latham MD and Ross WE: Proliferation-dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse and Chinese hamster ovary cells. Cancer Res 47: 3973-3979, 1987.
81. Giaccone G, Gazdar AF, Pizzorno G, Beck H, Zuzino F and Capranico G: Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression. Cancer Res 52: 1666-1671, 1992.
82. Kasahara K, Fujiwara Y, Sugimoto Y, Nishio K, Tamura T, Matsuda T and Saijo N: Determinants of response to the DNA topoisomerase II inhibitors doxorubicin and etoposide in human lung cancer cells. J Natl Cancer Inst 84: 113-118, 1992.
83. Caldecott K, Banks G and Jeggo P: DNA double-strand break repair pathways and cellular tolerance to inhibitors of topoisomerase II. Cancer Res 50: 5778-5783, 1990.
84. Deffie AM, Batra JK and Goldenberg GJ: Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and -resistant P388 leukemia cell lines. Cancer Res 49: 5866, 1989.
85. Fry AM, Chresta CM, Davies SM, Walker MC, Harris AL, Hartley JA, Masters JRW and Hickson ID: Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines. Cancer Res 51: 6592-6595, 1991.
86. Nitiss JL, Liu Y-X, Harbury P, Jannatipour M, Wasserman R and Wang JC: Amsacrine and etoposide hypersensitivity of yeast overexpressing DNA topoisomerase II. Cancer Res 52: 4467-4472. 1992.
87. Asano T, Herzog CE, Mayes J, McWatters A, Zwelling L and Kleinerman ES: Transfection of a Drosophila topoisomerase II gene sensitizes an intrinsically resistant human brain tumor cell line to etoposide. Proc Am. Assoc Cancer Res 36: #2637 (1995).
88. McPherson JP, Brown GA, Deuchars KL and Goldenberg GJ: Increased sensitivity to adriamycin in drug-resistant P388 murine leukemia cells transfected with human Topoisomerase IIα. Proc Am Assoc Cancer Res 36: #2641, 1995.
89. Woessner RD, Chung TDY, Hofmann GA, Mattern MR, Mirabelli CK, Drake FH and Johnson RK: Differences between normal and ras-transformed NIH-3T3 cells in expression of the 170kD and 180kD forms of topoisomerase II. Cancer Res 50: 2901-2908, 1990.
90. Utsugi T, Mattern MR, Mirabelli CK and Hanna N: Potentiation of topoisomerase inhibitor-induced DNA strand breakage and cytotoxicity by tumor necrosis factor: enhancement of topoisomerase activity as a mechanism of potentiation. Cancer Res 50: 2636-2640, 1990.
91. Cimoli G, Valenti M, Parodi S, Mazzoni A, De Sessa F, Conte P and Russo P: Reversal of "atypical"-multidrug resistance by recombinant human tumor necrosis factor in the human ovarian cancer ceil line A2780-DX3. Oncol Res 5: 311-323, 1993.
92. Valenti M, Cimoli G, Mariani GL, Conte PF, Parodi S and Russo O: Potentiation of TNF-mediated cell killing by mitoxantrone. Relationship to DNA single-strand break formation. Biochem Pharmacol 46: 1199-1206, 1993.
93. Valenti M, Cimoli G, Parodi S, Mariani GL, Venturini M, Conte P and Russo P: Potentiation of tumor necrosis factor-mediated cell killing by VP-16 on human ovarian cancer cell lines. In vitro results and clinical implications. Eur J Cancer 29a: 1157-1161, 1993.
94. Towatari M, Ito Y, Morishita Y, Tanimoto M, Kawashima K, Morishima Y, Andoh T and Saito H: Enhanced expression of DNA topoisomerase II by recombinant human granulocyte colonystimulating factor in human leukemia cells. Cancer Res 50: 7198-7202, 1990.
95. Drake FH, Hofmann GA, Bartus HF, Mattern MR, Crooke ST and Mirabelli CK: Biochemical and pharmacological properties of p 170 and p180 forms of topoisomerase II. Biochemistry 28: 8154-8160, 1989.
96. Boritzki TJ, Wolfard TS, Besserer JA, Jackson RC and Fry DW: Inhibition of type II topoisomerase by fostriecin. Biochem Pharmacol. 37: 4063-4068, 1988.
97. De Jong S, Zijlstra JG, Mulder NH and De Vries EGE: Lack of cross resistance to fostriecin in a human small cell lung carcinoma cell line showing topoisomerase II-related drug resistance. Cancer Chemother Pharmacol 28: 461-464, 1991.
98. Roberge M, Tudan C, Hung SMF, Harder KW, Jirik FR and Anderson H: Antitumor drug fostriecin inhibits the mitotic entry checkpoint and protein phosphatases 1 and 2A. Cancer Res 54: 6115-6121, 1994.
99. Chen M and Beck WT: Differences in inhibition of chromosome separation and G2 arrest by DNA topoisomerase II inhibitors merbarone and VM-26. Cancer Res 55: 1509-1516, 1995.
100. Drake FH, Hofmann GA, Mong SM, Bartus JO, Hertzberg RP, Johnson RK, Mattern MR and Mirabelli CK: In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone. Cancer Res 49: 2578-2583, 1989.
101. Jensen PB, Sorensen BS, Demant EJF, Sehested M, Jensen PS, Vindelov L and Hansen HH: Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4′-(9-acridinylamino) methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage. Cancer Res 50: 3311-3316, 1990.
102. Petersen LN, Jensen PB, Sorensen BS, Engelholm SA and Spangthomsen M: Postincubation with aclarubicin reverses topoisomerase II mediated DNA cleavage, strand breaks, and cytotoxicity induced by VP-16. Invest New Drugs 12: 289-297, 1994.
103. Tanabe K, Ikegami Y, Ishida R and Andoh T: Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives. Cancer Res 51: 4903-4980, 1991.
104. Ishida R, Miki T, Narita T, Yui R, Sato M, Utsumi KR, Tanabe K and Andoh T: Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors. Cancer Res 51: 49094916, 1991.
105. Poddevin B, Riou JF, Lavelle F and Pommier Y: Dual topoisomerase I and II inhibition by intoplicine (RP-60475). a new antitumor agent in early clinical trials. Mol Pharmacol 44: 767-774, 1993.
106. Trask DK and Muller MT: Stabilization of type I topoisomeraseDNA covalent complexes by actinomycin D. Proc Natl Acad Sci USA 85: 1417-1421, 1988.
107. Yamashita Y, Kawada SZ, Fujii N and Nakano H: Induction of mammalian DNA topoisomerase I and II mediated DNA cleavage by saintopin, a new antitumor agent from fungus. Biochemistry 30: 5838-5845, 1991.
108. Riou JF, Helissey P, Grondard L and Giorgi-Renault S: Inhibition of eukaryotic DNA topoisomerases I and II activities by indoloquinolinedione derivatives. Mol Pharmacol 40: 699-706, 1991.
109. Ling V: P-glycoprotein and resistance against anticancer drugs. Cancer 69: 2603-2609, 1992.
110. Cole SPC, Bhardway G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AMV and Deeley RG: Overexpression of a transporter gene in a multidrug-resistant lung cancer cell line. Science 258: 1650-1654, 1992.
111. Zaman GJR, Flens MJ, Van Leusden MR, De Haas M, Mulder HS, Lankelma J, Pinedo HM, Scheper RJ, Baas F. Broxterman HJ, et al: The human multidrug resistance-associated protein MRP is a plasma membrane drug-eMux pump. Proc Natl Acad Sci USA 91: 8822-8826, 1994.
112. De Jong S, Zijlstra JG, De Vries EGE and Mulder NH: Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res 50: 304-309, 1990.
113. Zwelling LA, Hinds M, Chan D, Mayes J, Sie KL, Parker E, Silberman L, Radcliffe A, Beran M and Blick M: Characterization of an amsacrine-resistant line of human leukemia cells. J Biol Chem 264: 16411-16420, 1989.
114. Sullivan DM, Latham MD, Rowe TC and Ross WE: Purification and characterization of an altered topoisomerase II from a drugresistant Chinese hamster ovary cell line. Biochemistry 28: 5680-5687, 1989.
115. Takano H and Fojo T: Acquired alternate splicing of topoisomerase IIα: A novel mechanism of resistance that defines a region of the gene with a role in nuclear translocation. Proc Am Assoc Cancer Res 36: #2693 (1995).
116. Markovits J, Pommier Y, Kerrigan D, Covey JM, Tilchen EJ and Kohn KW: Topoisomerase II-mediated DNA breaks and cytotoxicity in relation to cell proliteration and the cell cycle in NIH 3T3 fibroblasts and L1210 leukemia cells. Cancer Res 47: 2050-2055, 1987.
117. Hwang J and Hwong CL: Cellular regulation of mammalian DNA topoisomerases. Adv Pharmacol 29A: 167-189, 1994.
118. Tan KB, Mattern MR, Eng W-K. McCabe FL and Johnson RK: Nonreproductive rearrangement of DNA topoisomerase I and II genes:correlation with resistance to topoisomerase inhibitors. J Natl Cancer Inst 81: 1732-1735, 1989.
119. McPherson JP, Brown GA and Goldenberg GJ: Characterization of a DNA topoisomerase IIα gene rearrangement in adriamycin-resistant P388 leukemia: Expression of a fusion messenger RNA transcript encoding topoisomerase IIα and the retinoic acid receptor α locus. Cancer Res 53: 5885-5889, 1993.
120. Patel S and Fisher LM: Novel selection and genetic characterisation of an etoposide-resistant human leukemic CCRF-CEM cell line. Br J Cancer 67: 456-463, 1993.
121. Matsumura K, Isola J, Chew K, Henderson C, Smith HS, Harris HL, Hickson ID and Waldman F: Topoisomerase IIα deletion as well as amplification associated with erbB2 amplification in breast cancer. Proc Am Assoc Cancer Res 35: #2708, 1994.
122. Pommier Y, Kerrigan D, Covey JM, Kao-Shan CS and Whang-Peng J: Sister chromatid exchanges, chromosomal aberrations, and cytotoxicity produced by antitumor topoisomerase II inhibitors in sensitive (DC3F) and resistant (DC3F/9-OHE) Chinese hamster cells. Cancer Res 48: 512-516, 1988.
123. Backer LC, Allen JW, Harringtonbrock K, Campbell JA, Demarini DM, Doer CL, Howard DR, Kligerman AD and Moore MM: Genotoxicity of inhibitors of DNA topoisomerase-1 (camptothecin) and topoisomerase-II (m-AMSA) in vivo and in vitro. Mutagenesis 5: 541-547, 1990.
124. Ikeda H: DNA topoisomerase-mediated illegitimate recombination. Adv Pharmacol 29A: 147, 165, 1994.
125. Shibuya ML, Ueno AM, Vannais DB, Craven PA and Waldren CA: Megabase pair deletions in mutant mammalian cells following exposure to amsacrine, an inhibitor of DNA topoisomerase II. Cancer Res 54: 1092-1097, 1994.
126. Luethy JD and Holbrook NJ: Activation of the GADD153 promoter by genotoxic agents: A rapid and specific response to DNA damage. Cancer Res 52: 5-10, 1992.
127. Quesnel B, Kantarjian H, Bjergaard JP, Brault P, Estey E, Lai JL, Tilly H, Stoppa AM, Archimbaud E, Harousseau JL, Bauters F and Fenaux P: Therapy-related acute myeloid leukemia with t(8:21), inv(16), and t(8; 16): A report on 25 cases and review of the literature. J Clin Oncol 11: 2370-2379, 1993.
128. Ritke MK and Yalowich JC: Altered gene expression in human leukemia K562 cells selected for resistance to etoposide. Biochem Pharmacol 46: 2007-2020, 1993.
129. Feldhoff PW, Mirski SEL, Cole SPC and Sullivan DM: Altered subcellular distribution of topoisomerase IIα in a drug-resistant human small cell lung carcinoma cell line. Cancer Res 54: 756762, 1994.
130. Harker WG, Slade DL, Holguin MH: Characterization of an altered topoisomerase IIα mRNA expressed in a mitoxantrone-resistant cell line. Proc Am Assoc Cancer Res 36: #2684, 1995.
131. Ganapathi R, Zwelling L, Constantinou A, Ford J and Grabowski D: Altered phosphorylation, biosynthesis and degradation of the 170 kDa isoform of topoisomerase II in amsacrine-resistant human leukemia cells. Biochem Biophys Res Commun 192: 1274-1280, 1993.
132. Ritke MK, Allan WP, Fattman C, Gunduz NN and Yalowich JC: Reduced phosphorylation of topoisomerase II in etoposide-resistant human leukemia K562 cells. Mol Pharmacol 46: 58-66, 1994.
133. Takano H, Kohno K, Ono M, Uchida Y and Kuwano M: Increased phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of human cancer KB cells. Cancer Res 51: 3951-3957, 1991.
134. Harker WG, Slade DL, Drake FH and Parr RL: Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase IIß isoform. Biochemistry 30: 9953-9961, 1991.
135. Junqua S, Goldwasser F, Luccioni C, Beaumatin J., Saucier JM, Jacquemin-Sablon A and Markovits J: Alterations of DNA topoisomerase II and thymidine kinase in a human leukemic cell line selected for resistance to genistein. Proc Am Assoc Cancer Res 34: #1978, 1993.
136. Yamazaki K, Isobe H, Ogura S and Kawakami Y: Topoisomerase IIα content and topoisomerase IIß catalytic activity cannot explain drug sensitivities to topoisomerase inhibitors in lung cancer cell lines. Proc Am Assoc Cancer Res 36: #2663, 1995.
137. D'Andrea MR, Multhaupt HAD, Farber PA and Fogleson PD: Expression of genes for DNA topoisomerase IIα and DNA Topoisomerase IIß in human tumors. Proc Am Assoc Cancer Res 36: #2690, 1995.
138. Kim K, Hirabayashi N, Nishiyama M, Saeki S, Toge T and Okada K: Expression of MDR1, GST-π and topoisomerase II as an indicator of clinical response to adriamycin. Anticancer Res 11: 429-432, 1991.
139. Holden JA, Rolfson DH and Wittwer CT: Human DNA topoisomerase II: evaluation of enzyme activity in normal and neoplastic tissues. Biochemistry 29: 2127-2134, 1990.
140. Holden JA, Rolfson DH and Wittwer CT: The distribution of immunoreactive topoisomerase II protein in human tissues and neoplasms. Oncol Res 4: 157-166, 1992.
141. Van der Zee AGJ, Withoff S, Krans M and De Vries EGE: DNA topoisomerase I, IIα and IIß protein and RNA expression levels in human ovarian carcinoma. Proc Am Assoc Cancer Res 36: #2671, 1995.
142. Beck J, Niethammer D and Gekeler V: High mdrl- and mrp-, but low topoisomerase IIα-gene expression in B-cell chronic lymphocytic leukaemias. Cancer Lett 86: 135-142, 1994.
143. Vosberg HP: DNA topoisomerases: enzymes that control DNA conformation. Curr Top Microbiol Immunol 114: 19-102, 1985.
144. Barrett JF, Sutcliffe JA and Gootz TD: In vitro assays used to measure the activity of topoisomerases. Antimicrob Agents Chemother 34: 1-7, 1990.
145. Negri C, Chies R, Cerino A, Bestagno M, Sala C, Zini N, Maraldi NM and Astaldi Ricotti GCB: Monoclonal antibodies to human DNA topoisomerase I and the two isoforms of DNA topoisomerase II: 170- and 180-kDa isoenzymes. Exp Cetl Res 200: 452-459, 1992.
146. Robinson RG, Rapp L, Bowdish KJ, Graham MA, Huff AC and Coughlin SA: Isolation and characterization of monoclonal antibodies to a recombinant human topoisomerase II polypeptide. Hybridoma 12: 407-415, 1993.
147. Taagepera S, Rao PN, Drake FH and Gorbsky GJ: DNA topoisomerase II alpha is the major chromosome protein recognized by the mitotic phosphoprotein antibody MPM-2. Proc Natl Acad Sci USA 90: 8407-8411, 1993.
148. Mirski SEL, Evans CD, Almquist KC, Slovak ML and Cole SPC: Altered topoisomerase IIα in a drug-resistant small cell lung cancer cell line selected in VP-16. Cancer Res 53: 4866-4873, 1993.
149. Larsson R and Nygren P: Cytotoxic activity of topoisomerase II inhibitors in primary cultures of tumor cells from patients with human hematologic and solid tumors. Cancer 74: 2857-2862, 1994.
150. Stammler G, Sauerbrey A and Volm M: Determination of DNA topoisomerase II in newly diagnosed childhood acute lymphoblastic leukemia by immunocytochemistry and RT-PCR. Cancer Lett 84: 141-147, 1994.
151. Withoff S, Smit EF, Meersma GJ, Van den Berg A, TimmerBosscha H, Kok K, Postmus PE, Mulder NH, De Vries EGE and Buys CHCM: Quantitation of DNA topoisomerase IIα messenger ribonucleic acid levels in a small cell lung cancer cell line and two drug resistant sublines using a Polymerase Chain Reaction-aided transcript titration assay. Lab Invest 71: 61-66, 1994.
152. Kuho A, Nakagawa K, Fukuoka M, Yoshikawa A, Harashima T, Tamura K, Yana T, Masuda N, Matsui K, Kusunoki Y, Kawase I and Takada M: Identification of point mutations in the alphatopoisomerase II cDNA from human small cell lung cancer treated previously with etoposide. Proc Am Assoc Cancer Res 36: #2664, 1995.
153. Danks MK, Warmoth MR, Friche E, Granzen B, Bugg BY, Harker G, Zwelling LA, Futscher BW, Suttle DP and Beck WT: Single-strand conformational polymorphism analysis of the Mr 170,000 isoenzyme of DNA topoisomerase II in human tumor cells. Cancer Res 53: 1373-1379, 1993.
154. Danks MK, Beck WT and Suttle DP: Topoisomerase IIα mutation in leukemic cells from a patient with lineage switch AML. Proc Am Assoc Cancer Res 34: #1982, 1993.
155. Bugg BY, Danks MK, Beck WT and Suttle DP: Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide. Proc Natl Acad Sci USA 88: 7654-7658, 1991.
156. Gudkov AV, Zelnick CR, Kazarov AR, Thimmapaya R, Suttle DP, Beck WT and Roninson IB: Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cylotoxic drugs, from human topoisomerase II cDNA. Proc Natl Acad SCi USA 90: 3231-3235, 1993.
157. Gudkov AV, Kazarov AR, Thimmapaya R, Axenovich SA, Mazo IA and Roninson IB: Cloning mammalian genes by expression selection of genetic suppressor
158. Wasserman RA, Austin CA, Fisher M and Wang JC: Use of yeast in the study of anticancer drugs targeting DNA topoisomerases: Expression of a functional recombinant human DNA topoisomerase IIα in yeast. Cancer Res 53: 3591-3596, 1993.
159. Suttle DP, Reed RF and Goorha S: Baculovirus expression of wildtype and mutant topoisomerase II isoforms for analysis of drug resistance. Proc Am Assoc Cancer Res 36: #2681, 1995.
160. Furbee CS and Muller MT: Functional domain analysis of human topoisomerase II alpha. Proc Am Assoc Cancer Res 36: #2697, 1995.
161. Wang Q and Suttle DP: Conditional expression plasmids of human topoisomerase IIß to study its role in anticancer drug sensitivity/resistance. Proc Am Assoc Cancer Res 36: #2694, 1995.
162. Hsiang YH, Lihou MG and Liu LF: Arrest of replication forks by drug-stabilized topoisomerase IDNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49: 5077-5082, 1989.
163. Howard MT, Neece SH, Matson SW and Kreuzer KN: Disruption of a topoisomerase-DNA cleavage complex by a DNA helicase. Proc Natl Acad Sci USA 91: 12031-12035, 1994.
164. Hsiang YH, Lihou MG and Liu LF: Arrest of replication forks by drug-stabilized topoisomerase IDNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49: 50775082, 1989.
165. Liu LF: DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58:351-375, 1989.
166. Lowe SW, Ruley HE, Jacks T and Housman DE: P53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967, 1993.
167. Greenblatt MS, Bennett WP, Hollstein M, Harris CC: Mutations in the P53 tumor suppressor gene: Clues to cancer ethiology and molecular pathogenesis. Cancer Res 54: 4855-4878, 1994.
168. Van der Zee AGJ, Hollema H, Suurmeijer AJH, Krans M, Sluiter WJ, Willemse PHB, Aalders JG and De Vries EGE: The value of P-n, glutathione S-transferase pi, c-erbB-2 and P53 as prognostic factors in ovarian carcinomas. J Clin Oncol 13: 70-78, 1995.
169. Lee JM and Bernstein A: P53 mutations increase resistance to ionizing radiation. Proc Natl Acad Sci USA 90: 5742-5746, 1993.
170. Toffoli G, Doglioni C, Cernigio C, Frustaci S, Perin T, Canal B and Boiocchi M: P53 overexpression in human soft tissue sarcomas: Relation to biological aggressiveness. Ann Oncol 5: 167-172, 1994.
171. Fan S, el-Deiry WS, Bae I, Freeman J, Jondle D, Bhatia K, Fornace Jr AJ, Magrath I, Kohn KW and O'Connor PM: pS3 gene mutations are associated with decreased sensitivity of human Iymphoma cells to DNA damaging agents. Cancer Res 54: 5824-5830, 1994.
172. Brown R: P53: A target for new anticancer drugs or a target for old drugs? Ann Oncol 4: 623-629, 1993.
173. Dubrez L, Goldwasser F, Genne P, Pommier Y, Belon JP, Guy H and Solary E: The role of apoptosis and cell cycle regulation in determining leukemic cells sensitivity to topoisomerase poisons. Proc Am Assoc Cancer Res 36: #2468, 1995.
174. Findlay CA, Hinds PW and Levine AJ: The p53 protooncogene can act as a suppressor of transformation. Cell 57: 1083-1093, 1989.
175. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML and Wyllie AH: Thymocyte apoptosis induced by pS3 dependent and independent pathways. Nature 362: 849-852, 1993.
176. Lane DP: A death in the life of P53. Nature 362: 786-787, 1993.
177. Kamesaki S, Kamesaki H, Jorgensen TJ, Tanizawa A, Pommier Y and Cossman J: Bc1-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase IIinduced DNA strand breaks and their repair. Cancer Res 53: 4521-4526, 1993.
178. Hashimoto H, Chatterjee S and Berger NA: Bc1-2 protein inhibits etoposide (VP16)-induced genetic recombination and cytotoxicity. Proc Am Assoc Cancer Res 36: #2636, 1995.
179. D'Arpa P: Determinants of cellular sensitivity to topoisomerasetargeting antitumor drugs. Adv Pharmacol 29B: 127-141, 1994.
180. Kataoka S, Naito M, Tomida A and Tsuruo T: Resistance to antitumor agent-induced apoptosis in a mutant of human myeloid leukemia U937 cells. Exp Cell Res 215: 199-205, 1994.
181. Hinds M, Deisseroth K, Mayes J, Altschuler E, Jansen R, Ledley F and Zwelling L: Identification of a point mutation in the topoisomerase II gene from a human leukemia cell line containing an amsacrine-resistant form of topoisomerase II. Cancer Res 51: 4729-4731, 1991.
182. Lee MS, Wang JC and Beran M: Two independent amsacrine-resistant human myeloid leukemia cell lines share an identical point mutation in the 170 kDa form of human topoisomerase II. J Mol Biol 223: 837-843, 1992.
183. Campain JA, Gottesman MM and Pastan I: A novel mutant topoisomerase IIα present in VP-16resistant human melanoma cell lines has a deletion of alanine 429. Biochemistry 33: 11327-11332, 1994.
184. Takano H, Mickley L, Spengler B, Biedler JL and Fojo T: A topoisomerase II mutation in adriamycin-selected cells. Proc Am Assoc Cancer Res 34: #1983, 1993.